KORU Medical Systems, Inc. Financial Ratios
KRMD|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Altman Z-Score 1.40 (gray zone, between 1.23 and 2.9)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-36.1%
Profit Margin
-18.0%
Net Income / Revenue
Asset Turnover
1.19
Revenue / Total Assets
Equity Multiplier
1.68
Total Assets / Equity
Composite: -36.1% (reported: -36.1%)
Profitability
Liquidity
Current Ratio
2.44
Quick Ratio
1.99
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
1.19
Inventory Turnover
3.35
Days Sales Outstanding
67 days
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026
Earnings Quality
Accrual Ratio
-20.7%
+11.8pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.